Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Very early family-based intervention for anxiety: two case studies with toddlers.

Hirshfeld-Becker DR, Henin A, Rapoport SJ, Wilens TE, Carter AS.

Gen Psychiatr. 2019 Nov 21;32(6):e100156. doi: 10.1136/gpsych-2019-100156. eCollection 2019.

2.

Functional Impairment in Youth With ADHD: Normative Data and Norm-Referenced Cutoff Points for the Before School Functioning Questionnaire and the Parent Rating of Evening and Morning Behavior Scale, Revised.

Faraone SV, DeSousa NJ, Komolova M, Sallee FR, Incledon B, Wilens TE.

J Clin Psychiatry. 2019 Dec 10;81(1). pii: 19m12956. doi: 10.4088/JCP.19m12956.

3.

Editorial: Stimulants: Friend or Foe?

Wilens TE, Kaminski TA.

J Am Acad Child Adolesc Psychiatry. 2020 Jan;59(1):36-37. doi: 10.1016/j.jaac.2019.11.009. Epub 2019 Nov 20.

PMID:
31759095
4.

Considerations for Treating Young People With Comorbid Autism Spectrum Disorder and Substance Use Disorder.

Isenberg BM, Yule AM, McKowen JW, Nowinski LA, Forchelli GA, Wilens TE.

J Am Acad Child Adolesc Psychiatry. 2019 Dec;58(12):1139-1141. doi: 10.1016/j.jaac.2019.08.467.

PMID:
31757396
5.

Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.

Nielsen T, Bernson D, Terplan M, Wakeman SE, Yule AM, Mehta PK, Bharel M, Diop H, Taveras EM, Wilens TE, Schiff DM.

Addiction. 2020 Feb;115(2):291-301. doi: 10.1111/add.14825. Epub 2019 Nov 13.

PMID:
31692133
6.

Prescription Stimulants: From Cognitive Enhancement to Misuse.

Wilens TE, Kaminski TA.

Pediatr Clin North Am. 2019 Dec;66(6):1109-1120. doi: 10.1016/j.pcl.2019.08.006. Review.

PMID:
31679601
7.

The prevalence of unhealthy alcohol and drug use among inpatients in a general hospital.

Wakeman SE, Herman G, Wilens TE, Regan S.

Subst Abus. 2019 Aug 1:1-9. doi: 10.1080/08897077.2019.1635961. [Epub ahead of print]

PMID:
31368860
8.

Risk Factors for Overdose in Young People Who Received Substance Use Disorder Treatment.

Yule AM, Carrellas NW, DiSalvo M, Lyons RM, McKowen JW, Nargiso JE, Bergman BG, Kelly JF, Wilens TE.

Am J Addict. 2019 Sep;28(5):382-389. doi: 10.1111/ajad.12938. Epub 2019 Jul 10.

PMID:
31291042
9.

Risk Factors for Drug Overdose in Young People: A Systematic Review of the Literature.

Lyons RM, Yule AM, Schiff D, Bagley SM, Wilens TE.

J Child Adolesc Psychopharmacol. 2019 Aug;29(7):487-497. doi: 10.1089/cap.2019.0013. Epub 2019 Jun 27.

PMID:
31246496
10.

Sources of Nonmedical Prescription Drug Misuse Among US High School Seniors: Differences in Motives and Substance Use Behaviors.

McCabe SE, Veliz P, Wilens TE, West BT, Schepis TS, Ford JA, Pomykacz C, Boyd CJ.

J Am Acad Child Adolesc Psychiatry. 2019 Jul;58(7):681-691. doi: 10.1016/j.jaac.2018.11.018. Epub 2019 Mar 27.

PMID:
30926573
11.

Opioid Use Disorders in Adolescents-Updates in Assessment and Management.

Yule AM, Lyons RM, Wilens TE.

Curr Pediatr Rep. 2018 Jun;6(2):99-106. doi: 10.1007/s40124-018-0161-z. Epub 2018 Apr 25.

12.

Prescription Drug Misuse: Sources of Controlled Medications in Adolescents.

Schepis TS, Wilens TE, McCabe SE.

J Am Acad Child Adolesc Psychiatry. 2019 Jul;58(7):670-680.e4. doi: 10.1016/j.jaac.2018.09.438. Epub 2018 Oct 30.

PMID:
30768405
13.

Age-specific risk of substance use disorders associated with controlled medication use and misuse subtypes in the United States.

McCabe SE, Wilens TE, Boyd CJ, Chua KP, Voepel-Lewis T, Schepis TS.

Addict Behav. 2019 Mar;90:285-293. doi: 10.1016/j.addbeh.2018.11.010. Epub 2018 Nov 14.

PMID:
30472537
14.

Neuropsychological changes in patients with substance use disorder after completion of a one month intensive outpatient treatment program.

McKowen JW, Isenberg BM, Carrellas NW, Zulauf CA, Ward NE, Fried RS, Wilens TE.

Am J Addict. 2018 Dec;27(8):632-638. doi: 10.1111/ajad.12824. Epub 2018 Nov 2.

PMID:
30387896
15.

Attention-Deficit/Hyperactivity Disorder and Transitional Aged Youth.

Wilens TE, Isenberg BM, Kaminski TA, Lyons RM, Quintero J.

Curr Psychiatry Rep. 2018 Sep 17;20(11):100. doi: 10.1007/s11920-018-0968-x. Review.

PMID:
30221318
16.

Risk Factors for Depression in Adolescents With ADHD: The Impact of Cognitive Biases and Stress.

Shapero BG, Gibb BE, Archibald A, Wilens TE, Fava M, Hirshfeld-Becker DR.

J Atten Disord. 2018 Sep 10:1087054718797447. doi: 10.1177/1087054718797447. [Epub ahead of print]

PMID:
30198368
17.

Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts.

Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, Bharel M, Wilens TE, LaRochelle M, Walley AY, Land T.

Obstet Gynecol. 2018 Aug;132(2):466-474. doi: 10.1097/AOG.0000000000002734.

18.

Opioid Use Disorders: Perioperative Management of a Special Population.

Ward EN, Quaye AN, Wilens TE.

Anesth Analg. 2018 Aug;127(2):539-547. doi: 10.1213/ANE.0000000000003477. Review.

19.

Risk Factors for Overdose in Treatment-Seeking Youth With Substance Use Disorders.

Yule AM, Carrellas NW, Fitzgerald M, McKowen JW, Nargiso JE, Bergman BG, Kelly JF, Wilens TE.

J Clin Psychiatry. 2018 May/Jun;79(3). pii: 17m11678. doi: 10.4088/JCP.17m11678.

20.

Does exposure to parental substance use disorders increase offspring risk for a substance use disorder? A longitudinal follow-up study into young adulthood.

Yule AM, Wilens TE, Martelon M, Rosenthal L, Biederman J.

Drug Alcohol Depend. 2018 May 1;186:154-158. doi: 10.1016/j.drugalcdep.2018.01.021. Epub 2018 Mar 10.

21.

Sources of Prescription Medication Misuse Among Young Adults in the United States: The Role of Educational Status.

McCabe SE, Teter CJ, Boyd CJ, Wilens TE, Schepis TS.

J Clin Psychiatry. 2018 Mar/Apr;79(2). pii: 17m11958. doi: 10.4088/JCP.17m11958.

22.

Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.

Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.

J Child Adolesc Psychopharmacol. 2017 Aug;27(6):474-482. doi: 10.1089/cap.2017.0084. Epub 2017 Jul 21.

23.

Medical Cannabinoids in Children and Adolescents: A Systematic Review.

Wong SS, Wilens TE.

Pediatrics. 2017 Nov;140(5). pii: e20171818. doi: 10.1542/peds.2017-1818. Review.

24.

Pilot Data Supporting Omega-3 Fatty Acids Supplementation in Medicated Children with Attention-Deficit/Hyperactivity Disorder and Deficits in Emotional Self-Regulation.

Wilens TE, Carrellas NW, Zulauf C, Yule AM, Uchida M, Spencer A, Biederman J.

J Child Adolesc Psychopharmacol. 2017 Oct;27(8):755-756. doi: 10.1089/cap.2017.0080. Epub 2017 Jun 29. No abstract available.

25.

The Opioid Epidemic: What Is a Child Psychiatrist to Do?

Yule AM, Wilens TE, Rauch PK.

J Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):541-543. doi: 10.1016/j.jaac.2017.02.011. Epub 2017 Jun 21. No abstract available.

26.

To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine.

Anderson TA, Quaye ANA, Ward EN, Wilens TE, Hilliard PE, Brummett CM.

Anesthesiology. 2017 Jun;126(6):1180-1186. doi: 10.1097/ALN.0000000000001633. Review. No abstract available.

PMID:
28511196
27.

Neuropsychological functioning in college students who misuse prescription stimulants.

Wilens TE, Carrellas NW, Martelon M, Yule AM, Fried R, Anselmo R, McCabe SE.

Am J Addict. 2017 Jun;26(4):379-387. doi: 10.1111/ajad.12551.

28.

Adolescents' Prescription Stimulant Use and Adult Functional Outcomes: A National Prospective Study.

McCabe SE, Veliz P, Wilens TE, Schulenberg JE.

J Am Acad Child Adolesc Psychiatry. 2017 Mar;56(3):226-233.e4. doi: 10.1016/j.jaac.2016.12.008. Epub 2016 Dec 25.

29.

Examining the association between attention deficit hyperactivity disorder and substance use disorders: A familial risk analysis.

Yule AM, Martelon M, Faraone SV, Carrellas N, Wilens TE, Biederman J.

J Psychiatr Res. 2017 Feb;85:49-55. doi: 10.1016/j.jpsychires.2016.10.018. Epub 2016 Oct 22.

30.

Further Evidence for Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder.

Wilens TE, Biederman J, Martelon M, Zulauf C, Anderson JP, Carrellas NW, Yule A, Wozniak J, Fried R, Faraone SV.

J Clin Psychiatry. 2016 Oct;77(10):1420-1427. doi: 10.4088/JCP.14m09440.

31.

Predicting ADHD by Assessment of Rutter's Indicators of Adversity in Infancy.

Østergaard SD, Larsen JT, Dalsgaard S, Wilens TE, Mortensen PB, Agerbo E, Mors O, Petersen L.

PLoS One. 2016 Jun 29;11(6):e0157352. doi: 10.1371/journal.pone.0157352. eCollection 2016.

32.

Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study.

McCabe SE, Dickinson K, West BT, Wilens TE.

J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):479-86. doi: 10.1016/j.jaac.2016.03.011. Epub 2016 Apr 7.

33.

A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.

Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ.

J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):916-25.e2. doi: 10.1016/j.jaac.2015.08.016. Epub 2015 Sep 15.

PMID:
26506582
34.

Reliability and Validity of the Before-School Functioning Scale in Children With ADHD.

Faraone SV, Hammerness PG, Wilens TE.

J Atten Disord. 2018 Sep;22(11):1040-1048. doi: 10.1177/1087054714564623. Epub 2015 Jan 9.

PMID:
25575616
35.

Parental history of substance use disorders (SUD) and SUD in offspring: a controlled family study of bipolar disorder.

Wilens TE, Yule A, Martelon M, Zulauf C, Faraone SV.

Am J Addict. 2014 Sep-Oct;23(5):440-6. doi: 10.1111/j.1521-0391.2014.12125.x. Epub 2014 Mar 15.

36.

The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders.

Zulauf CA, Sprich SE, Safren SA, Wilens TE.

Curr Psychiatry Rep. 2014 Mar;16(3):436. doi: 10.1007/s11920-013-0436-6. Review.

37.

Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.

Wilens TE, McBurnett K, Turnbow J, Rugino T, White C, Youcha S.

J Atten Disord. 2017 Jan;21(2):110-119. doi: 10.1177/1087054713500144. Epub 2016 Jul 28.

PMID:
24071772
38.

Transitional aged youth: a new frontier in child and adolescent psychiatry.

Wilens TE, Rosenbaum JF.

J Am Acad Child Adolesc Psychiatry. 2013 Sep;52(9):887-90. doi: 10.1016/j.jaac.2013.04.020. No abstract available.

PMID:
23972688
39.

Does exposure to parental substance use disorders increase substance use disorder risk in offspring? A 5-year follow-up study.

Yule AM, Wilens TE, Martelon MK, Simon A, Biederman J.

Am J Addict. 2013 Sep-Oct;22(5):460-5. doi: 10.1111/j.1521-0391.2013.12048.x. Epub 2013 Apr 5.

PMID:
23952891
40.

Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Stevens JR, Wilens TE, Stern TA.

Prim Care Companion CNS Disord. 2013;15(2). pii: PCC.12f01472. doi: 10.4088/PCC.12f01472. Epub 2013 Mar 28. No abstract available.

41.

Difficulties in emotional regulation and substance use disorders: a controlled family study of bipolar adolescents.

Wilens TE, Martelon M, Anderson JP, Shelley-Abrahamson R, Biederman J.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):114-21. doi: 10.1016/j.drugalcdep.2013.01.015. Epub 2013 Feb 17.

42.

Substance-use disorders in adolescents and adults with ADHD: focus on treatment.

Wilens TE, Morrison NR.

Neuropsychiatry (London). 2012 Aug;2(4):301-312.

43.

Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.

Herring WJ, Wilens TE, Adler LA, Baranak C, Liu K, Snavely DB, Lines CR, Michelson D.

J Clin Psychiatry. 2012 Jul;73(7):e891-8. doi: 10.4088/JCP.11m07178.

PMID:
22901359
44.

Are obstetrical, perinatal, and infantile difficulties associated with pediatric bipolar disorder?

Martelon M, Wilens TE, Anderson JP, Morrison NR, Wozniak J.

Bipolar Disord. 2012 Aug;14(5):507-14. doi: 10.1111/j.1399-5618.2012.01027.x. Epub 2012 May 29.

45.

A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder.

Hammerness P, Zusman R, Systrom D, Surman C, Baggish A, Schillinger M, Shelley-Abrahamson R, Wilens TE.

World J Biol Psychiatry. 2013 May;14(4):299-306. doi: 10.3109/15622975.2012.678884. Epub 2012 May 6.

PMID:
22559155
46.

A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.

Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S.

J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):74-85.e2. doi: 10.1016/j.jaac.2011.10.012. Epub 2011 Nov 25.

PMID:
22176941
47.

Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine.

Wilens TE, Adler LA, Tanaka Y, Xiao F, D'Souza DN, Gutkin SW, Upadhyaya HP.

Curr Med Res Opin. 2011 Dec;27(12):2309-20. doi: 10.1185/03007995.2011.628648. Epub 2011 Oct 27.

48.

Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.

Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.

J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):978-90. doi: 10.1016/j.jaac.2011.07.018. Epub 2011 Sep 3. Review.

PMID:
21961773
49.

An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Wilens TE, Morrison NR, Prince J.

Expert Rev Neurother. 2011 Oct;11(10):1443-65. doi: 10.1586/ern.11.137. Review.

50.

Genome-wide association study of the child behavior checklist dysregulation profile.

Mick E, McGough J, Loo S, Doyle AE, Wozniak J, Wilens TE, Smalley S, McCracken J, Biederman J, Faraone SV.

J Am Acad Child Adolesc Psychiatry. 2011 Aug;50(8):807-17.e8. doi: 10.1016/j.jaac.2011.05.001. Epub 2011 Jul 13.

Supplemental Content

Loading ...
Support Center